Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Food and Chemical Toxicology 162 (2022) 112901

Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox

The prognostic role of micronutrient status and supplements in COVID-19 outcomes: A systematic review

Evmorfia Pechlivanidou [a], Dimitrios Vlachakis [b], Konstantinos Tsarouhas [c], Dimitris Panidis [d], Christina Tsitsimpikou [e], Christina Darviri [f], Dimitrios Kouretas [g], Flora Bacopoulou [a,f,*]

[a] Center for Adolescent Medicine and UNESCO Chair in Adolescent Health Care, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Athens, 11527, Greece
[b] Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and Biotechnology, Agricultural University of Athens, Athens, 11855, Greece
[c] Department of Cardiology, University Hospital of Larissa, Mezourlo, Larissa, 41110, Greece
[d] European Commission, Joint Research Centre (JRC), Ispra, Italy
[e] General Chemical State Laboratory of Greece, 16, An. Tsocha Str., Athens, 11521, Greece
[f] Postgraduate Program "The Science of Stress and Health Promotion", School of Medicine, National and Kapodistrian University of Athens, 4 Soranou Ephessiou Street, 11527, Athens, Greece
[g] Department of Biochemistry and Biotechnology, University of Thessaly, Larissa, Greece

ARTICLE INFO

Handling Editor: Dr. Jose Luis Domingo

Keywords:
COVID-19
Vitamin
Supplements
Pandemic
Micronutrients
Coronavirus

ABSTRACT

Micronutrients constitute an adjuvant treatment for respiratory viral infections. Since there is no effective antiviral therapy for COVID-19 yet, adjuvant intervention for the survival of critically ill patients may be significant. Search of the PubMed, CINAHL and Cochrane databases was carried out to find human studies investigating the prognostic role of micronutrient status and the effects of micronutrient supplementation intervention in COVID-19 outcomes of adult patients. Patients with certain comorbidities (diabetes mellitus type 2, obesity, renal failure, liver dysfunction etc.) or pregnant women were excluded. 31 studies (27 observational studies and 4 clinical trials) spanning the years 2020–2021, pertaining to 8624 COVID-19 patients (mean age±SD, 61 ± 9 years) were included in this systematic review. Few studies provided direct evidence on the association of serum levels of vitamin D, calcium, zinc, magnesium, phosphorus and selenium to patients' survival or death. Vitamin D and calcium were the most studied micronutrients and those with a probable promising favorable impact on patients. This review highlights the importance of a balanced nutritional status for a favorable outcome in COVID-19. Micronutrients' deficiency on admission to hospital seems to be related to a high risk for ICU admission, intubation and even death. Nevertheless, evidence for intervention remains unclear.

1. Introduction

In December 2019, the Municipal Health Commission of Wuhan identified a large number of cases of viral pneumonia of unknown etiology. Soon, through sequence analysis, a new virus of the coronavirus family was identified and named SARS-CoV-2, while the resulting disease was named Corona Virus Induced Disease 2019 (COVID-19) (Zhu et al., 2020). By February 2020 the widespread transmission of the virus outside China became apparent, while on March 12, 2020, the World Health Organization (WHO) characterized the situation as a pandemic (WHO, 2020a). In early February 2021 the cases had exceeded 100 million worldwide, while over 2 million people had lost their lives due to COVID-19 (WHO, 2020b).

While SARS-CoV-2 seems to be accompanied by lower mortality rates than the previous corona viruses MERS and SARS-CoV-1, it is more contagious (Lu et al., 2020; Wang et al., 2020). Current estimates of mortality rates range from 0.5 to 3.5% overall (compared to 0.1% for seasonal flu) and are significantly higher in the elderly, people with comorbidities, or the immunosuppressed. Key risk factors are age over 65 years, coronary heart disease, heart failure, diabetes mellitus, chronic obstructive pulmonary disease, obesity and smoking (Guo et al., 2020; Huang et al., 2020a; Wang et al., 2020).

Vaccination has been proven a safe and efficient strategy against SARS-CoV-2 spread, the rapidity of which has substantially reduced the

* Corresponding author. Center for Adolescent Medicine and UNESCO Chair in Adolescent Health Care, Choremeio Research Laboratory, First Department of Pediatrics, Aghia Sophia Children's Hospital, Athens, 11527, Greece.
E-mail address: fbacopoulou@med.uoa.gr (F. Bacopoulou).

https://doi.org/10.1016/j.fct.2022.112901
Received 9 January 2022; Received in revised form 17 February 2022; Accepted 22 February 2022
Available online 25 February 2022
0278-6915/© 2022 Elsevier Ltd. All rights reserved.

number of new COVID-19 cases and their severity in highly vaccinated countries, while microRNAs have been introduced as promising antiviral agents aside from their crucial use in vaccine technology (Abedi et al., 2021). However, antiviral treatment and evidence of other favorable interventions need further development (Tavilani et al., 2021; Whittaker et al., 2021). Regarding prognosis, risk factors have been clarified but recovery predictors are still under research (Abrahim et al., 2020; Alvarez-Esteban et al., 2021; Ny et al., 2021; Rydwik et al., 2021; Tolossa et al., 2021).

Recent reviews agree that micronutrients play a crucial role in COVID-19 progression, prognosis and survival, as in multiple other viral infections that primarily affect the respiratory tract (Cheng, 2020; Grant et al., 2020; Rozga et al., 2021; Zhang and Liu, 2020). The well-known essential role of vitamins, minerals, metalloids and other micronutrients in many biological, biochemical and molecular processes along with in vivo studies demonstrating a significant role of several micronutrients in COVID-19, led clinicians use micronutrients as a promising adjuvant therapy against SARS-CoV-2 severe pneumonia (Domingo and Marquès, 2021; Thakur et al., 2021). The already studied nutritional interventions for SARS-CoV and MERS-CoV infections and the underlying mechanism *via* which micronutrients inhibit these viruses are encouraging, as SARS-CoV-2 shares a 79.5% sequence identity with SARS-CoV and 50% with MERS-CoV (Jin et al., 2020; Jin et al., 2020; Zhu et al., 2020). Especially zinc and flavonoids have been proven to inhibit a special protease of the virus called 3C and improve survival (Jo et al., 2019, 2020; Keil et al., 2016; Lin et al., 2017; Ryu et al., 2010).

This systematic review summarizes and describes human studies investigating the prognostic role of micronutrient status and the effects of micronutrient supplementation intervention in COVID-19 outcomes of adult patients.

2. Materials and methods

2.1. Search strategy

The present systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic and comprehensive search of the PubMed, CINAHL and Cochrane databases was carried out for papers published from database inception until April 27, 2021. We used the following search algorithm: ("Wuhan coronavirus" or "Wuhan virus" or "novel coronavirus" or "nCoV" or "SARS-CoV-2″ or "SARS 2″ or "severe acute respiratory syndrome coronavirus 2″ or "COVID-19″ or "coronavirus disease 2019 virus" or "2019-nCoV" or "2019 novel coronavirus" or "severe acute respiratory syndrome coronavirus 2″ or "coronavirus" or "coronaviruses") AND ("Vitamin D″ or "vitamin D″ or "25-OH-calciferol" or "25 hydroxy calciferol " or "25-OH-vit D″ or "25-OH-vitamin d" or "25 hydroxy vitamin d" or Mg or zinc or "vitamin C″ or "ascorbate" or "ascorbic acid" or Ca or antioxidants or micronutrients) AND patients AND prognosis. The references of all eligible articles were also checked thoroughly.

2.2. Selection criteria

The eligibility criteria were based on the PICOS (Participants, Intervention, Comparison, Outcomes, Study design) acronym. Studies of COVID-19 inpatients, outpatients or both were included in the review, if they fulfilled the following criteria: (i) written in English language; (ii) investigated outcomes among SARS-CoV-2 infected adults according to specific micronutrients' blood levels; (iii) were prospective or retrospective cohort studies or cross-sectional studies or clinical trials; (iv) the study presented its final results; (v) there was a precise determination of the patients' levels of the studied micronutrient at the beginning and/or during the study protocol, so that objective evidence of the sufficiency or insufficiency of the studied micronutrient could be provided. Regarding the determination of prognosis, all studies looking for outcomes such as severe disease, need for mechanical ventilation (MV), intensive care unit (ICU) admission, mortality, end or duration of hospitalization, reduction of blood inflammatory markers and those estimating certain survival scores were included, to enclose only studies with specific or measurable outcomes. Studies were excluded if they focused only on patients with certain comorbidities (such as diabetes mellitus type 2, obesity, renal failure, liver dysfunction etc.) or pregnant women. These populations were excluded because their pre-comorbid conditions might had precluded potentially beneficial effects of vitamin supplements, whereas pregnant women might had already been taking nutrient supplements to maintain adequate micronutrient levels throughout gestation. Studies evaluating prognosis only throughout the improvement of symptoms were also excluded.

2.3. Quality assessment and data extraction

Titles and abstracts of studies were retrieved using the search strategy for all three databases and were extracted independently by three different authors (EP, DV and FB). These authors (EP, DV and FB) screened for eligibility the titles and abstracts of the retrieved papers and analyzed the full-text articles that met the eligibility criteria. Data extraction was performed as following: first author and year of publication, studied micronutrient, country, study design, demographic information (age, sex), sample size, COVID-19 test type for diagnosis, time of micronutrients laboratory evaluation, criteria for prognosis evaluation, results. Automation tools were not used in this process.

2.4. Compliance with ethics guidelines

This article is a review of previously conducted studies, in accordance with the PRISMA guidelines.

3. Results

3.1. Search results and selection of studies

Initial search yielded 186 studies. After excluding irrelevant papers and those matching to the research subject but not complying with the eligibility criteria, the final step of the screening process resulted in 31 studies (14 published in 2020 and 17 in 2021) spanning the years 2020–2021. Among included studies, 27 were observational studies (19 retrospective, 4 prospective, 4 cross-sectional) and 4 were clinical trials (2 double-blind placebo-controlled). The PRISMA flow diagram shows the selection and exclusion of studies (Fig. 1).

Fourteen studies focused on vitamin D (Vit D) levels as a key-micronutrient in prognosis, 12 on calcium (Ca), 4 on zinc (Zn), 4 on magnesium (Mg), 3 on phosphorus (P), 2 on vitamin C (Vit C), 2 on selenium (Se), 2 on folate while iron (Fe), vitamin B12 (Vit B12), vitamin E (Vit E), melatonin, N-acetylcysteine and pentoxifylline were also studied.

3.2. Study characteristics

This systematic review included 8624 COVID-19 patients with a mean age of 61 years. Among them 527 participated in clinical trials. Three studies (2 observational and 1 clinical trial) included COVID-19 patients who had been admitted to the ICU since their first hospitalization day (Chavarría et al., 2021; Vassiliou et al., 2020; Zheng et al., 2021).

As outcomes indicating prognosis most studies (21/31) used mortality or survival as primary or secondary outcomes (Alamdari et al., 2020; Bennouar et al., 2021; Capone et al., 2020; Carpagnano et al., 2021; Doaei et al., 2021; Entrenas Castillo et al., 2020; Ersoz and Yilmaz, 2021; Heller et al., 2021; Infante et al., 2021; Karahan and Katkat, 2021; Kashefizadeh et al., 2020; Lohia et al., 2021; Meisel et al., 2021; Moghaddam et al., 2020; Murai et al., 2021; Radujkovic et al., 2020; Sun



Fig. 1. PRISMA flow diagram of study selection.

et al., 2020; Tehrani et al., 2021; Tezcan et al., 2020; Vassiliou et al., 2020; Zheng et al., 2021). ICU admission or need for such admission was studied in 9/31 studies (Capone et al., 2020; Entrenas Castillo et al., 2020; Ersoz and Yilmaz, 2021; Lagier et al., 2020; Liu et al., 2020; Maghbooli et al., 2020; Murai et al., 2021; Tezcan et al., 2020; Yang et al., 2021), 9/31 studies used "length of hospitalization" (Capone et al., 2020; Entrenas Castillo et al., 2020; Ersoz and Yilmaz, 2021; Lagier et al., 2020; Liu et al., 2020; Maghbooli et al., 2020; Murai et al., 2021; Tezcan et al., 2020; Yang et al., 2021), MV was used by 5/31 (Liu et al., 2020; Murai et al., 2021; Radujkovic et al., 2020; Sun et al., 2020; Tezcan et al., 2020), blood levels of inflammatory markers were used by 8/31 (Carpagnano et al., 2021; Chavarría et al., 2021; Karahan and Katkat, 2021; Liu et al., 2020; Maghbooli et al., 2020; Radujkovic et al., 2020; Ricci et al., 2021; Yang et al., 2021) and 3/31 used already known weighted scores (Chavarría et al., 2021; Doaei et al., 2021; Ricci et al., 2021).

Almost all studies estimated blood levels of targeted micronutrients for all patients at least on admission. COVID-19 diagnosis was confirmed by polymerase chain reaction (PCR) test for all patients in all studies.

The main characteristics and results of the studies are presented in Tables 1 and 2, respectively.

3.3. Results on the prognostic role of each micronutrient

3.3.1. Vitamin D (Vit D)

Most studies in this systematic review focused on prognostic role of Vit D in COVID-19. Most observational studies presented Vit D blood levels on admission as prognostic factors given that in 5 studies survivors revealed higher levels on admission than non-survivors, while in 2 studies Vit D deficiency was related to higher mortality risk ratio (Bennouar et al., 2021; Carpagnano et al., 2021; Infante et al., 2021; Karahan and Katkat, 2021; Kashefizadeh et al., 2020; Radujkovic et al., 2020; Ricci et al., 2021; Tehrani et al., 2021; Vassiliou et al., 2020). MV was more common among patients with Vit D deficiency than patients with normal Vit D levels in a single study (Radujkovic et al., 2020). Inflammatory markers on admission were higher among patients with low Vit D levels than the rest or an inverse association between Vit D levels and inflammatory markers was detected (Carpagnano et al., 2021; Karahan and Katkat, 2021; Maghbooli et al., 2020; Radujkovic et al., 2020; Ricci et al., 2021). Finally, 4/14 studies concluded that Vit D was not associated to prognosis of COVID-19 patients (Allard et al., 2020; Ersoz and Yilmaz, 2021; Lohia et al., 2021; Murai et al., 2021), whereas one clinical trial targeting Vit D levels, reported significantly lower risk for ICU admission of the intervention group vs. controls, with only 1 patient receiving Vit D supplementation admitted to ICU (Entrenas Castillo et al., 2020).

3.3.2. Calcium (Ca)

Ca levels constituted a prognostic factor for COVID-19 patients. Survival was associated with normocalcemia and higher Ca levels (within normal limits) were related to higher survival rates (Bennouar et al., 2021; Kashefizadeh et al., 2020; J. Liu et al., 2020; Sun et al., 2020; Zheng et al., 2021). Low Ca levels were also a prognostic marker for the development of severe disease (Yang et al., 2021; Zhao et al., 2021). Duration of hospitalization and ICU admission were related to low admission Ca blood levels in some cases (Wu et al., 2020; Yang et al., 2021) whereas in 3 studies Ca was not a useful biomarker for prognosis (Alamdari et al., 2020; Allard et al., 2020; Tezcan et al., 2020).

Table 1
Main characteristics of included studies, study samples and micronutrients.

	First author, year	Micronutrient	Country	WHO region	Type of study	COVID-19 patients N	Age in years, mean (SD)	Females N (%)
1.	Chavarría et al., 2021	Vit C Vit E N-acetylcysteine Melatonin Pentoxifylline	Mexico	Americas	Clinical Trial (non-double-blind placebo-controlled)	110 in ICU	58 (13)	32 (29%)
2.	Ricci et al. (2021)	Vit D	Italy	Europe	Prospective	52 with lung involvement (22 Vit D deficient vs. 30 with normal Vit D)	77.5 (16) vs. 68.9 (18)	13 (59%) vs. 14 (47%)
3.	Infante et al. (2021)	Vit D	Italy	Europe	Retrospective	137 (78 survivors vs. 59 non-survivors)	65 (28) vs. 70 (29)	48 (35%)
4.	Ersoz and Yilmaz (2021)	Vit D Fe Vit B12 Folate	Turkey	Europe	Retrospective	310	57 (18)	149 (48)
5.	Kashefizadeh et al. (2020)	Ca Mg	Iran	Eastern Mediterranean	Retrospective	53	58 (13)	29 (55%)
6.	Zheng et al. (2021)	Ca	China	Western Pacific	Retrospective	180 in ICU	64	67 (37%)
7.	Karahan and Katkat (2021)	Vit D	Turkey	Europe	Retrospective	149	63 (15)	68 (46%)
8.	Bennouar et al. (2021)	Vit D Ca	Algeria	Africa	Prospective	120 critically ill	62 (18)	37 (31%)
9.	Lohia et al. (2021)	Vit D	USA	Americas	Retrospective	270 severely ill	64 (15)	153 (57%)
10.	Zhao et al. (2021)	Ca	China	Western Pacific	Retrospective	172 moderately ill (on admission)	65 (5)	90 (52%)
11.	Allard et al. (2020)	Zn Se Ca P Mg Vit D	France	Europe	Retrospective	108	62 (16)	44 (41%)
12.	Heller et al. (2021)	Zn Se	Germany	Europe	Cross-sectional	31	77 (5)	19 (54%)
13.	Maghbooli et al. (2020)	Vit D	Iran	Eastern Mediterranean	Cross-sectional	235	59 (15)	91 (39%)
14.	Radujkovic et al. (2020)	Vit D	Germany	Europe	Retrospective	185	60 (9)	90 (49%)
15.	Yang et al. (2021)	Ca P	China	Western Pacific	Retrospective	226 (104 confirmed patients and 122 suspected cases)	40 (4)	89 (39%)
16.	Jothimani et al. (2020)	Zn	India	South-East Asia	Prospective	47	34 (6)	18 (38%)
17.	Alamdari et al. (2020)	Ca Mg	Iran	Eastern Mediterranean	Cross-sectional	459	62 (12)	139 (30%)
18.	Tezcan et al. (2020)	Ca	Turkey	Europe	Retrospective	408	54 (16)	220 (54%)
19.	Entrenas Castillo et al. (2020)	Vit D	Spain	Europe	Clinical Trial (non-double-blind placebo-controlled)	76 inpatients	53 (10)	31 (41%)
20.	Capone et al. (2020)	Vit C Zn	USA	Americas	Retrospective	102	63 (3)	47 (46%)
21.	Carpagnano et al. (2021)	Vit D	Italy	Europe	Retrospective	42 (acute respiratory failure) inpatients to Respiratory Intermediate Care Unit	65 (13)	12 (29%)
22.	Moghaddam et al. (2020)	Se	Germany	Europe	Cross-sectional	33	77 (5)	19 (54%)
23.	Liu et al. (2020)	Ca	China	Western Pacific	Retrospective	107 severely ill	68 (2)	55 (51%)
24.	Lagier et al., 2020	Zn	France	Europe	Retrospective	3737	45 (17)	2033 (54%)
25.	Sun et al. (2020)	Ca Vit D	China	Western Pacific	Retrospective	241	65 (2)	129 (54%)
26.	Wu et al. (2020)	Ca	China	Western Pacific	Retrospective	125 discharged	55 (4)	59 (47)
27.	Meisel et al. (2021)	Folate	Israel	Europe	Retrospective	333	65 (3)	115 (35%)
28.	Doaei et al. (2021)	Omega-3 fatty acids	Iran	Eastern Mediterranean	Clinical Trial (double-blind placebo-controlled)	101 critically ill (28 intervention group *vs.* 73 control group)	66 (15) vs. 64 (14)	13 (46%) vs 28 (38%)
29.	Tehrani et al. (2021)	Vit D	Iran	Eastern Mediterranean	Retrospective	205 critically ill	60 (15)	79 (39%)
30.	Murai et al. (2021)	Vit D	Brazil	Americas	Clinical Trial (double-blind placebo-controlled)	240	56 (14)	104 (44%)
31.	Vassiliou et al. (2020)	Vit D	Greece	Europe	Prospective	30 in ICU	65 (11)	6 (20%)

Ca: calcium, COVID-19: Corona Virus Induced Disease 2019, Fe: iron, ICU: intensive care unit, Mg: magnesium, P: phosphorus, Se: selenium, Vit D: Vitamin D, Vit B12: Vitamin B12, Vit C: Vitamin C, Vit E: Vitamin E, Zn: zinc.

Table 2
Main results and protocols of included studies.

	First author, year	Micronutrients	Laboratory evaluations	Study protocol COVID-19 patient categories	Prognosis evaluation	Results
1.	Chavarría et al., 2021	Vit C Vit E N-acetylcysteine Melatonin Pentoxifylline	Baseline (day before treatment) and each day of treatment	• Per os or NG tube • 5 groups • Each group received pentoxifylline and 4/5 one of the other studied micronutrients • Treatment: every 12 h for 5 days	• SOFA, Apache II, SAPS II, Critical Illness Risk Score, COVIDGRAM and GCS scores •Inflammatory markers (CRP, IL-6, PCT)	IL-6 decreased in Vit C + Pentoxifylline, Vit E + Pentoxifylline, and NAC + Pentoxifylline treatments CRP decreased with all treatments PCT decreased in Vit C + Px, Vit E + Px and NAC + Px groups Antioxidant therapies improved all survival scores
2.	Ricci et al. (2021)	Vit D	Hospital admission	Vit D deficient (<10 ng/ml) or not	• SOFA, LIPI and TS scores • IL-6, hs-CRP, PCT	Higher IL-6 in Vit D deficient patients on admission Higher SOFA, LIPI and TS scores in patients with Vit D deficiency Higher mortality rate in Vit D deficient patients
3.	Infante et al., 2021	Vit D	Hospital admission	Survivors Non-survivors	Mortality	Higher Vit D in survivors *vs.* non-survivors Inverse association between Vit D and risk of in-hospital mortality
4.	Ersoz and Yilmaz (2021)	Vit D Fe Vit B12 Folate	Hospital admission	2 groups (ICU admission, intubation and death)	ICU admission Intubation Mortality	Higher Vit B12 in ICU or intubation patients and non-survivors Lower Fe in worse prognosis patients for all three factors Lower folate in patients in need for ICU admission
5.	Kashefizadeh et al. (2020)	Ca Mg	Hospital admission	Survivors Non-survivors	Length of hospitalization Mortality	Significantly lower Ca of non-survivors *vs.* survivors Insignificantly lower Mg on admission of survivors *vs.* non-survivors
6.	Zheng et al. (2021)	Ca	Every day	Survivors Non-survivors	Mortality	Significantly lower Ca on admission and on day of death of non-survivors *vs.* survivors
7.	Karahan and Katkat (2021)	Vit D	Hospital admission	Survivors Non-survivors	COVID-19 Severity Mortality Inflammatory markers including CRP	Lower Vit D in patients with severe-critical disease *vs.* moderate disease 93% of critically ill patients presented with Vit D insufficiency Vit D levels higher in survivors Vit D independently associated with mortality and negatively related to CRP
8.	Bennouar et al. (2021)	Vit D Ca	Hospital admission	Vit D: • deficient ≤20 ng/ml • insufficient 21–29 ng/ml • normal ≥30 ng/ml	In-hospital mortality within 28 days of admission	Significantly lower Ca and Vit D on admission of non-survivors *vs.* survivors Significant dose effect relation between both Vit D and Ca to mortality ratio (highest mortality ratio in patients with lowest levels for both micronutrients)
9.	Lohia et al. (2021)	Vit D	Hospital admission	Categorized according to each outcome separately	Mortality MV Thromboembolism (DVT, PE)	No association of Vit D with mortality, MV, ICU admission, thromboembolism
10.	Zhao et al. (2021)	Ca	Hospital admission	Categorized according to 2 outcomes	Critical illness or discharge with mild disease	Low Ca was a risk factor for severe disease Significantly lower Ca in severe *vs.* moderate disease
11.	Allard et al. (2020)	Zn Se Ca P Mg Vit D	Hospital admission	Categorized according to levels of each micronutrient separately	Severe COVID-19 pneumonia	Lower Zn, P and higher Mg in severe disease
12.	Heller et al. (2021)	Zn Se	Mean 5th (SD = 4) day of hospitalization	Survivors Non-survivors	Mortality	Most patients Zn deficient Zn significantly lower in non-survivors *vs.* survivors Zn increased consistently in both survivors and non-survivors throughout hospitalization Linear association between Zn and Se

(*continued on next page*)

Table 2 (*continued*)

	First author, year	Micronutrients	Laboratory evaluations	Study protocol COVID-19 patient categories	Prognosis evaluation	Results
						Increasing Se day-by-day in survivors vs. stable Se in non-survivors
13.	Maghbooli et al. (2020)	Vit D	Hospital admission	Categorized according to Vit D cut-off: 30 ng/ml	Duration of Hospitalization ICU admission Severe disease (CDC criteria) CRP levels>40 mg/dl	Higher CRP in Vit D insufficient patients Vit D sufficiency independently associated with decreased disease severity No differences in hospitalization duration and ICU admissions between patients with or without Vit D sufficiency
14.	Radujkovic et al. (2020)	Vit D	Hospital admission	Inpatients Outpatients Median observation: 66 days	IMV Mortality IL-6 levels for inpatients	Vit D-deficient patients: • more commonly inpatients than outpatients • higher risk of IMV and/or death • higher median IL-6 at hospitalization
15.	Yang et al. (2021)	Ca P	Hospital admission ICU admission Discharge	Categorized according to each outcome independently	Disease severity (moderate vs. severe/critical) CT score ICU admission (+days of staying) Hospitalization days Inflammation markers	Significantly low P commonly detected in severe disease Low Ca in severe disease. Significantly more patients with low P and/or low Ca admitted to ICU *vs.* patients with normal levels Low Ca and P significantly correlated with low CT scores
16.	Jothimani et al. (2020)	Zn	6 h post- admission	Categorized according to Zn cut-off: 80 μg/dl All patients received multivitamins, including Vit C 500 mg bd and Zn 150 mg OD (after the test) as per standard care	Duration of hospitalization Disease severity	Zn deficient patients *vs.* patients with normal levels: • significantly more complications • significantly higher IL-6 • more hospitalization days • higher trend of death
17.	Alamdari et al. (2020)	Ca Mg	Hospital admission	Categorized according to studied outcome	Mortality	Survivors had significantly higher Mg on admission than those who died
18.	Tezcan et al. (2020)	Ca	Hospital admission	Categorized according to each studied outcome	ICU admission MV Duration of hospitalization Mortality	OR = 0.14 (NS) for mortality of hypocalcemic *vs.* normocalcemic patients on admission
19.	Entrenas Castillo et al. (2020)	Vit D	Hospital admission or day before treatment	Intervention group Control group (2:1 ratio) Intervention: oral calcifediol (0.532 mg) on admission (day 1) and 0.266 mg on day 3 and 7 and then the same dose once weekly until discharge or ICU admission	ICU admission Mortality	Significantly higher ICU admissions for control *vs.* intervention group Among patients receiving Vit D supplementation only 1 admitted to ICU
20.	Capone et al. (2020)	Vit C Zn	Hospital admission	73 received Vit C and Zn supplementation during treatment	Mortality ICU admission	Supplementation not associated with survival
21.	Carpagnano et al. (2021)	Vit D	12 h post-hospital admission	4 groups according to Vit D: • without hypovitaminosis ≥30 ng/mL • insufficient 20–30 ng/mL • moderately deficient 10–20 ng/ml • severely deficient <10 ng/ml	Morbidity Mortality Inflammatory markers (IL-6, CRP)	Tendency to higher IL-6 in patients with severe Vit D deficiency *vs.* all other groups Tendency to rapid unfavorable clinical evolution of patients with severe Vit D deficiency *vs.* all other groups 50% mortality risk in patients severely deficient *vs.* 5% in patients moderately deficient
22.	Moghaddam et al. (2020)	Se	Mean 5th (SD = 4) day of hospitalization	Survivors Non-survivors	Mortality	Significantly higher Se in survivors *vs.* non-survivors Se recovered with time in survivors but remained low or declined in non-survivors
23.	Liu et al. (2020)	Ca	Hospital admission	Categorized according to corrected serum Ca cut-off < 2.15 mmol/L	Inflammation markers (IL-6, PCT, CRP) Poor outcome: need for MV, ICU admission or death of any cause during admission	Negative correlation of Ca with all inflammatory markers Significantly lower Ca in patients with poor outcome Significantly lower Ca on admission in non survivors than the rest
24.	Lagier et al., 2020	Zn	Hospital admission	Poor outcome Favorable outcome	Poor outcome: ICU admission, death, hospitalization lasting ≥10 days	Low Zn significantly associated with poor outcomes

(*continued on next page*)

Table 2 (*continued*)

	First author, year	Micronutrients	Laboratory evaluations	Study protocol COVID-19 patient categories	Prognosis evaluation	Results
25.	Sun et al. (2020)	Ca Vit D	Within 24 h of hospital admission all patients tested for Ca levels 26 patients tested for Vit D levels according to clinical needs	3 groups according to serum Ca: • ≤2.0 mmol/L • 2.0–2.2 mmol/L • >2.2 mmol/L All 26 patients had Vit D deficiency (mean = 10.2 ng/mL, SD = 0.7 ng/mL)	Septic shock Organ injury MODS 28-day mortality MV Continuous renal replacement therapy	Positive correlation between Ca and Vit D Higher 28-day mortality and organ injury incidence for patients with low Ca Lower Ca among non-survivors and patients with MODS, septic shock, organ injury, requiring MV or continuous renal replacement therapy
26.	Wu et al. (2020)	Ca	Hospital admission	Categorized according to total hospitalization stay	Duration of hospitalization (cut-off: 14 days)	Significantly lower Ca on admission in patients with hospitalization length >14 days *vs.*< 14 days
27.	Meisel et al. (2021)	Folate	At least once during hospitalization	Categorized according to folate levels (cut-off: 5.9 ng/mL = 13.37 nmol/L) for primary analysis and then divided into 4 groups • <7.4 ng/mL • 7.4–10.4 ng/mL • 10.4–14.8 ng/mL • >14.8 ng/mL	Mortality Invasive ventilatory support Length of hospital stay Acute kidney injury	No difference between patients with normal *vs.* decreased folate Decreased folate not associated with increased mortality risk or composite outcome of intubation and mortality risk Non-significant results after grouping patients according to folate level quartiles
28.	Doaei et al. (2021)	Omega-3 fatty acids	Baseline and 14 days of intervention	28 received fortified formula with n3-PUFA 73 controls 1 month observation	Apache II GCS Mortality	Significantly higher 1-month survival rate of intervention group
29.	Tehrani et al. (2021)	Vit D	Hospital admission	Categorized both according to disease severity (moderate = 162 *vs.* severe = 43) and Vit D status: • very low <10 ng/ml • insufficient 10–30 ng/ml • sufficient 30–100 ng/ml • toxic >100 ng/ml	Mortality	Significant difference in Vit D levels between improved and deceased patients only in severely ill patients
30.	Murai et al. (2021)	Vit D	Baseline	120 received single oral dose 200,000 IU Vit D *vs.* 120 received placebo	Hospitalization duration Mortality ICU admission MV	No significant differences in endpoints
31.	Vassiliou et al. (2020)	Vit D	ICU admission	2 groups: higher and lower than median value of the cohort (cut-off: 15.2 ng/mL)	28-day ICU mortality	All patients who died within 28 days belonged to the low Vit D group Low Vit D group had higher 28-day mortality probability Non-survivors critically ill patients had lower ICU admission Vit D *vs.* survivors

bd: twice a day, Ca: calcium, COVID-19: Corona Virus Induced Disease 2019, DVT: deep vein thrombosis, Fe: iron, GCS: Glasgow Coma Scale/Score, ICU: intensive care unit, IL-6:interleukin-6, IMV: invasive mechanical ventilation, LIPI: Lung Immune Prognostic Index, Mg: magnesium, MV: mechanical ventilation MODS: multiple organ dysfunction syndrome, OD: once a day, P: phosphorus, PE: pulmonary embolism, Se: selenium, SAPS: Simplified Acute Physiology Score, SOFA: Sequential Organ Failure assessment, TS: total score, Vit D: Vitamin D, Vit B12: Vitamin B12, Vit C: Vitamin C, Vit E: Vitamin E, Zn: zinc.

3.3.3. *Zinc (Zn)*

Low Zn blood levels were associated with the development of severe disease, more complications or longer hospitalization (Allard et al., 2020; Jothimani et al., 2020; Lagier et al., 2020). In some cases, survival was associated with high admission Zn levels (Heller et al., 2021; Lagier et al., 2020) but this was not verified in all studies (Capone et al., 2020).

3.3.4. *Selenium (Se), Phosphate (P) and Magnesium (Mg)*

Survival was associated with high blood levels of Se (Heller et al., 2021; Moghaddam et al., 2020), Mg (Alamdari et al., 2020; Kashefizadeh et al., 2020), P (Yang et al., 2021). Similarly, severe disease was inversely associated to P and Mg levels (Allard et al., 2020).

Several clinical trials suggested that micronutrients' supplementation was helpful in clinical improvement and survival of COVID-19 patients (Chavarría et al., 2021; Doaei et al., 2021; Entrenas Castillo et al., 2020; Murai et al., 2021).

4. Discussion

This review examines whether micronutrient status of COVID-19 patients is related to the course and outcome of the disease but even a year after the characterization of COVID-19 as a pandemic, direct evidence is still weak. Previous experience on the treatment of other SARS and viral infections suggests that nutrition may alter the outcome even in critically ill patients (Rowe et al., 2021). In addition, the activation of inflammation and development of an effective immune system are primarily associated to nutrition utilization (Marcos et al., 2003). The importance of inflammation in COVID-19 prognosis has been highlighted in survival analysis, as neutrophil-to-lymphocyte ratio and white blood cells have been introduced as one-month mortality predictors in COVID-19 (Vafadar Moradi et al., 2021). Nutrient deficiency alters cells regeneration and function, suppresses immune response, and contributes to diabetes mellitus type II, hypertension and coronary heart disease in the elderly (Bjorklund et al., 2020; Farrokhian et al., 2016;

Holmberg et al., 2017; Langley-Evans and Carrington, 2006).

COVID-19 has a multiplex pathophysiology and alters different metabolic pathways. Excess inflammation, endothelial damage, and the use of angiotensin converting enzyme 2 (ACE-2) as crucial cellular entrance for the virus, consist fundamental mechanisms of SARS-CoV-2 action. The suppression of the pathways involved in lung tissue destruction by specialized micromolecular agents such as Rho kinase inhibitors, along with the efficiency of multiple micronutrients targeting these processes, may promisingly result in boosting the immune response against the viral agent (Abedi et al., 2020).

Vit D has been proposed to have a special place on the cell protection mechanism by inhibiting the entrance of the virus in the cells *via* interaction of Vit D with its one receptor and ACE-2 (Glaab and Ostaszewski, 2020). Also, Vit D enablement is crucial for immune function as it participates to the pathways of function for normal T-cells, macrophages, dendritic cells and other immune cells (Aranow, 2011; Sigmundsdottir et al., 2007). Its role in the PLC-γ1 expression through a specific nuclear receptor is also mandatory for both the innate and adaptive immune systems (von Essen et al., 2010). Most human studies on COVID-19 patients agree that Vit D within normal limits on admission may assist in a favorable outcome. This finding strengthens the hypotheses that Vit D acts both as an immune booster and an antiviral agent. The molecular mechanism that may explain the benefit of Vit D supplementation in COVID-19 patients is its immunomodulatory effect on interleukin-6 (IL-6) production. Vit D reduces immune cell IL-6 production, and potentially reduces pro-inflammatory effects, but it does not specifically target IL-6 receptors, avoiding any negative impact on IL-6 anti-inflammatory actions (Silberstein, 2020). Furthermore, human studies have revealed a significant immunomodulatory capacity of Vit D to lower tumor necrosis factor (TNF) and interleukin-10 (IL-10) levels (Peterson and Heffernan, 2008; Schleithoff et al., 2006). Thus, multiple pathways are probably activated by Vit D and result in favorable immunoregulation against COVID-19, as IL-6, IL-10 and TNF are primarily involved in excess inflammation in COVID-19 severe illness (Pedersen and Ho, 2020). These findings, combined with the results of this systematic review, provide evidence for the use of Vit D as adjuvant factor targeting hyperinflammatory cytokines in COVID-19. Nevertheless, more clinical trials are needed to evaluate the action of Vit D supplements both in Vit D deficient patients and patients without insufficiency, along with its beneficial effects against the virus per se.

Calcium is along with Vit D the most studied molecule among critically ill COVID-19 patients. Hypocalcemia was a known abnormality accompanying multiple viral infections before the outbreak of COVID-19, thus low Ca levels among these patients were expected (Crespi and Alcock, 2021; Huang et al., 2020; Nathan et al., 2020). Although the exact pathophysiological mechanism causing this abnormality has not been clarified yet and multiple hypotheses including malnutrition of the elderlies, disturbed albumin binding and parathyroid hormone secretion caused by COVID-19 as well as the role of unsaturated fat elevation, have been proposed (Cappellini et al., 2020; Crespi and Alcock, 2021; Huang et al., 2020; Nathan et al., 2020; Torres et al., 2021). Two recent metanalyses studying hypocalcemia as a risk factor for critically illness and intubation, revealed that hypocalcemia was related to high D-dimer levels and thus a more inflammatory response to SARS-CoV-2 (Alemzadeh et al., 2021; Paliogiannis et al., 2020). Vice versa, our results indicate that normal Ca levels act protectively as they are related to survival. It is important to underline that SARS-CoV-2 cellular hypoxia leads to alteration of Ca cell signaling and results in great increase of intracellular Ca through two different processes: i) hijacking the Ca channels and pumps, thus intracellular Ca cannot get out of the cell and ii) enhancing the cellular entry of extracellular Ca obligatory for the translation of HIF-1α and HIF-2α, a process stimulated by hypoxia (Danta, 2020, 2021; Gusarova et al., 2011; Hui et al., 2006; Serebrovska et al., 2020). This pathophysiological process gives evidence that patients with normal serum Ca levels may not be attacked by SARS-CoV-2 in such a degree that cellular hypoxia has absorbed most of the extracellular Ca and that could explain why normocalcaemia on admission is related to survival. If this hypothesis works, Ca supplements cannot act as an adjuvant therapy targeting SARS-CoV-2 inflammatory cascade but only as a protective therapy to the crucial consequences of hypocalcemia itself.

Zinc belongs to minerals/metalloids and constitutes a co-factor for several enzymes participating in antioxidant reactions that assist the immune system (Black, 2003). Zn deficiency disturbs the development of immune cells and thus cell-mediated immunity but also humeral immunity (Maares and Haase, 2016; Skalny et al., 2020; Tuerk and Fazel, 2009). In clinical practice Zn deficiency has been related both to viral infections and severe pneumonia among the elderly and has been effective as a nutrient supplement in the recovery from common cold (Barnett et al., 2010; Mossad et al., 1996; Read et al., 2019). Zn has been found to participate in the molecular pathways of acute respiratory syndrome, as animal studies have proved that Zn deficiency results in significant increase in proinflammatory molecules along with lung epithelium remodeling and thus in increased permeability of proinflammatory markers that lead the cell to apoptosis (Bao and Knoell, 2006; Biaggio et al., 2010; Liu et al., 2014; St Croix et al., 2005). Zn deficiency may also participate in the inflammatory process that results in lung fibrosis (Biaggio et al., 2012). As for COVID-19, the aforementioned mechanisms may explain the clinical improvement of patients with normal Zn levels compared to those with Zn deficiency while a reverse association between Zn and IL-6 levels as well as Zn capability to inhibit SARS-CoV-2 RNA polymerase are described (Domingo and Marquès, 2021). In addition, in vitro experiments give indications that Zn may target and inhibit the SARS-CoV-2 agent itself (Iyigundogdu et al., 2017; Zhang and Liu, 2020). If we further consider the fact that Zn has worked as an adjuvant therapy in acute respiratory syndrome along with the results of the present review, Zn appears to be a promising nutrient supplement as an adjuvant treatment for COVID-19 patients (Haider et al., 2011; Skalny et al., 2020). Nevertheless, large scale clinical studies are needed to confirm this hypothesis.

This review indicates that other metalloids such as Se and Mg may relate to the prognosis of patients with SARS-CoV-2 infection. Mg is a crucial co-factor for multiple enzymatic reactions and low levels of Mg have been related to increased proinflammatory and inflammatory markers as well as molecules that disturb the normal endothelial function (Chacko et al., 2010). Selenium has been discussed as a crucial biomarker for the prognosis of multiple viral infections including influenza, coxsackie virus, cytomegalovirus and hepatitis C. Abnormal low levels of this molecule have been related to high pathogenicity of influenza and suppressed immune response against the agent (Chacko et al., 2010; Harthill, 2011; Steinbrenner et al., 2015). Domingo and Marquès reviewed the role of Se in regulating the host defense against SARS-CoV-2 and corroborate the immunomodulatory properties of this metalloid as well as the negative role of Se deficiency in COVID-19 patients (Domingo and Marquès, 2021). Phosphate participates in cell and tissue regeneration. Thus, high P levels may assist the cellular effort to maintain alive during the infection. However, neither animal nor in vivo studies have clarified the exact pathways and findings from human studies remain weak (Kumar et al., 2021). Other micronutrients that are discussed to act beneficially against SARS-CoV-2 but findings from human studies and clinical trials are not clear, are Vit C, Vit E, Fe, copper and other antioxidants (Cheng, 2020; Domingo and Marquès, 2021; Tavakol and Seifalian, 2021; Tojo et al., 2021).

5. Conclusion

The COVID-19 pandemic is a major threat to human life all over the world. The absence of an effective anti-SARS-CoV-2 treatment trace each possible favorable adjuvant therapy vital for the survival of critical and non-critical ill patients. This systematic review highlights the importance of a healthy micronutrient status for a favorable outcome in COVID-19. Vit D, Ca and Zn may make a significant difference if used as

nutritional supplements on a primary point, but further clinical trials need to confirm it. In addition, micronutrients' deficiency on admission seems to be related with high risk for ICU admission, intubation and even death. Thus, it is important for individuals to maintain a healthy and balanced nutritional status to overcome a possible COVID-19 infection while further studies are required to evaluate if vitamin supplements would assist or not, a vaccinated or not individual, to actually contract SARS-CoV-2.

CRediT authorship contribution statement

Evmorfia Pechlivanidou: Project administration, Conceptualization, Investigation, Methodology, Writing – original draft. **Dimitrios Vlachakis:** Investigation, Methodology, Writing – original draft. **Konstantinos Tsarouhas:** Investigation, Writing – original draft. **Dimitris Panidis:** Visualization, Writing – original draft. **Christina Tsitsimpikou:** Visualization, Writing – original draft. **Christina Darviri:** Supervision, Writing – review & editing. **Dimitrios Kouretas:** Supervision, Writing – review & editing. **Flora Bacopoulou:** Project administration, Investigation, Methodology, Supervision, Writing – review & editing.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Abedi, F., Rezaee, R., Karimi, G., 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against severe acute respiratory syndrome coronavirus 2 (COVID-19). Pharmacol. Res. 156, 104808. https://doi.org/10.1016/j.phrs.2020.104808.

Abedi, F., Rezaee, R., Hayes, A.W., Nasiripour, S., Karimi, G., 2021. MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents? Cell Cycle 20 (2), 143–153. https://doi.org/10.1080/15384101.2020.1867792.

Abrahim, S.A., Tessema, M., Defar, A., Hussen, A., Ejeta, E., Demoz, G., Tereda, A.B., Dillnessa, E., Feleke, A., Amare, M., Nigatu, F., Fufa, Y., Refera, H., Aklilu, A., Kassa, M., Kifle, T., Whiting, S., Tollera, G., Abate, E., 2020. Time to recovery and its predictors among adults hospitalized with COVID-19: a prospective cohort study in Ethiopia. PLoS One 15 (12), e0244269. https://doi.org/10.1371/journal.pone.0244269.

Alamdari, N.M., Afaghi, S., Rahimi, F.S., Tarki, F.E., Tavana, S., Zali, A., Fathi, M., Besharat, S., Bagheri, L., Pourmotahari, F., Irvani, S., Dabbagh, A., Mousavi, S.A., 2020. Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran. Tohoku J. Exp. Med. 252 (1), 73–84. https://doi.org/10.1620/tjem.252.73.

Alemzadeh, E., Alemzadeh, E., Ziaee, M., Abedi, A., Salehiniya, H., 2021. The effect of low serum Ca level on the severity and mortality of Covid patients: a systematic review and meta-analysis. Immun Inflamm Dis. https://doi.org/10.1002/iid3.528.

Allard, L., Ouedraogo, E., Molleville, J., Bihan, H., Giroux-Leprieur, B., Sutton, A., Baudry, C., Josse, C., Didier, M., Deutsch, D., Bouchaud, O., Cosson, E., 2020. Malnutrition: percentage and association with prognosis in patients hospitalized for Coronavirus Disease 2019. Nutrients 12 (12), 3679. https://doi.org/10.3390/nu12123679.

Alvarez-Esteban, P.C., Del Barrio, E., Rueda, O.M., Rueda, C., 2021. Predicting COVID-19 progression from diagnosis to recovery or death linking primary care and hospital records in Castilla y Leon (Spain). PLoS One 16 (9), e0257613. https://doi.org/10.1371/journal.pone.0257613.

Aranow, C., 2011. Vitamin D and the immune system. J. Invest. Med. 59 (6), 881–886. https://doi.org/10.2310/JIM.0b013e31821b8755.

Bao, S., Knoell, D.L., 2006. Zinc modulates cytokine-induced lung epithelial cell barrier permeability. Am. J. Physiol. Lung Cell Mol. Physiol. 291 (6), L1132–L1141. https://doi.org/10.1152/ajplung.00207.2006.

Barnett, J.B., Hamer, D.H., Meydani, S.N., 2010. Low zinc status: a new risk factor for pneumonia in the elderly? Nutr. Rev. 68 (1), 30–37. https://doi.org/10.1111/j.1753-4887.2009.00253.x.

Bennouar, S., Cherif, A.B., Kessira, A., Bennouar, D.E., Abdi, S., 2021. Vitamin D deficiency and low serum Ca as predictors of poor prognosis in patients with severe COVID-19. J. Am. Coll. Nutr. 40 (2), 104–110. https://doi.org/10.1080/07315724.2020.1856013.

Biaggio, V.S., Perez Chaca, M.V., Valdez, S.R., Gomez, N.N., Gimenez, M.S., 2010. Alteration in the expression of inflammatory parameters as a result of oxidative stress produced by moderate zinc deficiency in rat lung. Exp. Lung Res. 36 (1), 31–44. https://doi.org/10.3109/01902140903061787.

Biaggio, V.S., Salvetti, N.R., Perez Chaca, M.V., Valdez, S.R., Ortega, H.H., Gimenez, M.S., Gomez, N.N., 2012. Alterations of the extracellular matrix of lung during zinc deficiency. Br. J. Nutr. 108 (1), 62–70. https://doi.org/10.1017/S0007114511005290.

Bjorklund, G., Dadar, M., Pivina, L., Dosa, M.D., Semenova, Y., Aaseth, J., 2020. The role of Zinc and Copper in insulin resistance and diabetes mellitus. Curr. Med. Chem. 27 (39), 6643–6657. https://doi.org/10.2174/0929867326666190902122155.

Black, R.E., 2003. Zinc deficiency, infectious disease and mortality in the developing world. J. Nutr. 133 (5 Suppl. 1), 1485S–1489S. https://doi.org/10.1093/jn/133.5.1485S.

Capone, S., Abramyan, S., Ross, B., Rosenberg, J., Zeibeq, J., Vasudevan, V., Samad, R., Gerolemou, L., Pinelis, E., Gasperino, J., Orsini, J., 2020. Characterization of critically ill COVID-19 patients at a brooklyn safety-net hospital. Cureus 12 (8), e9809. https://doi.org/10.7759/cureus.9809.

Cappellini, F., Brivio, R., Casati, M., Cavallero, A., Contro, E., Brambilla, P., 2020. Low levels of total and ionized Ca in blood of COVID-19 patients. Clin. Chem. Lab. Med. 58 (9), e171–e173. https://doi.org/10.1515/cclm-2020-0611.

Carpagnano, G.E., Di Lecce, V., Quaranta, V.N., Zito, A., Buonamico, E., Capozza, E., Palumbo, A., Di Gioia, G., Valerio, V.N., Resta, O., 2021. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. J. Endocrinol. Invest. 44 (4), 765–771. https://doi.org/10.1007/s40618-020-01370-x.

Chacko, S.A., Song, Y., Nathan, L., Tinker, L., de Boer, I.H., Tylavsky, F., Wallace, R., Liu, S., 2010. Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women. Diabetes Care 33 (2), 304–310. https://doi.org/10.2337/dc09-1402.

Chavarría, A.P., Vázquez, R., Cherit, J., Bello, H.H., Suastegui, H.C., Moreno-Castañeda, L., Alanís Estrada, G., Hernández, F., González-Marcos, O., Saucedo-Orozco, H., Manzano-Pech, L., Márquez-Velasco, R., Guarner-Lans, V., Pérez-Torres, I., Soto, M.E., 2021. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. Comput. Struct. Biotechnol. J. 19, 1379–1390. https://doi.org/10.1016/j.csbj.2021.02.009.

Cheng, R.Z., 2020. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Med Drug Discov 5, 100028. https://doi.org/10.1016/j.medidd.2020.100028.

Crespi, B., Alcock, J., 2021. Conflicts over Ca and the treatment of COVID-19. Evol Med Public Health 9 (1), 149–156. https://doi.org/10.1093/emph/eoaa046.

Danta, C.C., 2020. Ca Channel Blockers: a possible potential therapeutic strategy for the treatment of Alzheimer's dementia patients with SARS-CoV-2 infection. ACS Chem. Neurosci. 11 (15), 2145–2148. https://doi.org/10.1021/acschemneuro.0c00391.

Danta, C.C., 2021. SARS-CoV-2, hypoxia, and Ca signaling: the consequences and therapeutic options. ACS Pharmacol Transl Sci 4 (1), 400–402. https://doi.org/10.1021/acsptsci.0c00219.

Doaei, S., Gholami, S., Rastgoo, S., Gholamalizadeh, M., Bourbour, F., Bagheri, S.E., Samipoor, F., Akbari, M.E., Shadnoush, M., Ghorat, F., Mosavi Jarrahi, S.A., Ashouri Mirsadeghi, N., Hajipour, A., Joola, P., Moslem, A., Goodarzi, M.O., 2021. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. J. Transl. Med. 19 (1), 128. https://doi.org/10.1186/s12967-021-02795-5.

Domingo, J.L., Marquès, M., 2021. The effects of some essential and toxic metals/metalloids in COVID-19: a review. Food Chem. Toxicol. 152, 112161. https://doi.org/10.1016/j.fct.2021.112161.

Entrenas Castillo, M., Entrenas Costa, L.M., Vaquero Barrios, J.M., Alcala Diaz, J.F., Lopez Miranda, J., Bouillon, R., Quesada Gomez, J.M., 2020. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J. Steroid Biochem. Mol. Biol. 203, 105751. https://doi.org/10.1016/j.jsbmb.2020.105751.

Ersoz, A., Yilmaz, T.E., 2021. The association between micronutrient and hemogram values and prognostic factors in COVID-19 patients: a single-center experience from Turkey. Int. J. Clin. Pract., e14078 https://doi.org/10.1111/ijcp.14078.

Farrokhian, A., Bahmani, F., Taghizadeh, M., Mirhashemi, S.M., Aarabi, M.H., Raygan, F., Aghadavod, E., Asemi, Z., 2016. Selenium supplementation affects insulin resistance and serum hs-CRP in patients with type 2 diabetes and coronary heart disease. Horm. Metab. Res. 48 (4), 263–268. https://doi.org/10.1055/s-0035-1569276.

Glaab, E., Ostaszewski, M., 2020. The Role of Spike-ACE2 Interaction in Pulmonary Blood Pressure Regulation. FAIRDOM Hub.

Grant, W.B., Lahore, H., McDonnell, S.L., Baggerly, C.A., French, C.B., Aliano, J.L., Bhattoa, H.P., 2020. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12 (4). https://doi.org/10.3390/nu12040988.

Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., Lu, Z., 2020. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19). JAMA cardiology 5 (7), 811–818. https://doi.org/10.1001/jamacardio.2020.1017.

Gusarova, G.A., Trejo, H.E., Dada, L.A., Briva, A., Welch, L.C., Hamanaka, R.B., Mutlu, G. M., Chandel, N.S., Prakriya, M., Sznajder, J.I., 2011. Hypoxia leads to Na,K-ATPase downregulation via Ca(2+) release-activated Ca(2+) channels and AMPK activation. Mol. Cell Biol. 31 (17), 3546–3556. https://doi.org/10.1128/MCB.05114-11.

Haider, B.A., Lassi, Z.S., Ahmed, A., Bhutta, Z.A., 2011. Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age. Cochrane Database Syst. Rev. 10, CD007368. https://doi.org/10.1002/14651858.CD007368.pub2.

Harthill, M., 2011. Review: micronutrient S deficiency influences evolution of some viral infectious diseases. Biol. Trace Elem. Res. 143 (3), 1325–1336. https://doi.org/10.1007/s12011-011-8977-1.

Heller, R.A., Sun, Q., Hackler, J., Seelig, J., Seibert, L., Cherkezov, A., Minich, W.B., Seemann, P., Diegmann, J., Pilz, M., Bachmann, M., Ranjbar, A., Moghaddam, A., Schomburg, L., 2021. Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker. Redox Biol. 38, 101764. https://doi.org/10.1016/j.redox.2020.101764.

Holmberg, S., Rignell-Hydbom, A., H Lindh, C., Jönsson, B.A., Thelin, A., Rylander, L., 2017. High levels of vitamin D associated with less ischemic heart disease – a nested case-control study among rural men in Sweden. Ann. Agric. Environ. Med. 24 (2), 288–293. https://doi.org/10.5604/12321966.1235176.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., Cao, B., 2020a. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395 (10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

Huang, I., Lim, M.A., Pranata, R., 2020b. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 14 (4), 395–403. https://doi.org/10.1016/j.dsx.2020.04.018.

Hui, A.S., Bauer, A.L., Striet, J.B., Schnell, P.O., Czyzyk-Krzeska, M.F., 2006. Ca signaling stimulates translation of HIF-alpha during hypoxia. Faseb. J. 20 (3), 466–475. https://doi.org/10.1096/fj.05-5086com.

Infante, M., Buoso, A., Pieri, M., Lupisella, S., Nuccetelli, M., Bernardini, S., Fabbri, A., Iannetta, M., Andreoni, M., Colizzi, V., Morello, M., 2021. Low vitamin D status at admission as a risk factor for poor survival in hospitalized patients with COVID-19: an Italian retrospective study. J. Am. Coll. Nutr. 1 https://doi.org/10.1080/07315724.2021.1877580. –16.

Iyigundogdu, Z.U., Demir, O., Asutay, A.B., Sahin, F., 2017. Developing novel antimicrobial and antiviral textile products. Appl. Biochem. Biotechnol. 181 (3), 1155–1166. https://doi.org/10.1007/s12010-016-2275-5.

Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., Duan, G., 2020. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 12 (4), 372. https://doi.org/10.3390/v12040372.

Jo, S., Kim, H., Kim, S., Shin, D.H., Kim, M.S., 2019. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem. Biol. Drug Des. 94 (6), 2023–2030. https://doi.org/10.1111/cbdd.13604.

Jo, S., Kim, S., Shin, D.H., Kim, M.S., 2020. Inhibition of SARS-CoV 3CL protease by flavonoids. J. Enzym. Inhib. Med. Chem. 35 (1), 145–151. https://doi.org/10.1080/14756366.2019.1690480.

Jothimani, D., Kailasam, E., Danielraj, S., Nallathambi, B., Ramachandran, H., Sekar, P., Manoharan, S., Ramani, V., Narasimhan, G., Kaliamoorthy, I., Rela, M., 2020. COVID-19: poor outcomes in patients with zinc deficiency. Int. J. Infect. Dis. 100, 343–349. https://doi.org/10.1016/j.ijid.2020.09.014.

Karahan, S., Katkat, F., 2021. Impact of Serum 25(OH) Vitamin D level on mortality in patients with COVID-19 in Turkey. J. Nutr. Health Aging 25 (2), 189–196. https://doi.org/10.1007/s12603-020-1479-0.

Kashefizadeh, A., Ohadi, L., Golmohammadi, M., Araghi, F., Dadkhahfar, S., Kiani, A., Abedini, A., Fadaii, A., Ghojoghi, A., Nouraie, M., Tabary, M., 2020. Clinical features and short-term outcomes of COVID-19 in Tehran, Iran: an analysis of mortality and hospital stay. Acta Biomed. : Atenei Parmensis 91 (4), e2020147. https://doi.org/10.23750/abm.v91i4.10206.

Keil, S.D., Bowen, R., Marschner, S., 2016. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion 56 (12), 2948–2952. https://doi.org/10.1111/trf.13860.

Kumar, P., Kumar, M., Bedi, O., Gupta, M., Kumar, S., Jaiswal, G., Rahi, V., Yedke, N.G., Bijalwan, A., Sharma, S., Jamwal, S., 2021. Role of vitamins and minerals as immunity boosters in COVID-19. Inflammopharmacology 29 (4), 1001–1016. https://doi.org/10.1007/s10787-021-00826-7.

Lagier, J.C., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A., Honoré, S., Gaubert, J.Y., Fournier, P.E., Tissot-Dupont, H., Chabrière, E., Stein, A., Deharo, J.C., Fenollar, F., Rolain, J.M., Obadia, Y., Jacquier, A., La Scola, B., Brouqui, P., Drancourt, M., Parola, P., Raoult, D., IHU COVID-19 Task force, 2020. Outcomes of 3,737 COVID-19 patients treated withhydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Trav. Med. Infect. Dis. 36 https://doi.org/10.1016/j.tmaid.2020.101791, 101791.

Langley-Evans, S.C., Carrington, L.J., 2006. Diet and the developing immune system. Lupus 15 (11), 746–752. https://doi.org/10.1177/0961203306070001.

Lin, S.C., Ho, C.T., Chuo, W.H., Li, S., Wang, T.T., Lin, C.C., 2017. Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect. Dis. 17 (1), 144. https://doi.org/10.1186/s12879-017-2253-8.

Liu, J., Han, P., Wu, J., Gong, J., Tian, D., 2020. Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health 13 (9), 1224–1228. https://doi.org/10.1016/j.jiph.2020.05.029.

Liu, M.J., Bao, S., Napolitano, J.R., Burris, D.L., Yu, L., Tridandapani, S., Knoell, D.L., 2014. Zinc regulates the acute phase response and serum amyloid A production in response to sepsis through JAK-STAT3 signaling. PLoS One 9 (4), e94934. https://doi.org/10.1371/journal.pone.0094934.

Lohia, P., Nguyen, P., Patel, N., Kapur, S., 2021. Exploring the link between vitamin D and clinical outcomes in COVID-19. Am. J. Physiol. Endocrinol. Metab. 320 (3), E520–E526. https://doi.org/10.1152/ajpendo.00517.2020.

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W.J., Wang, D., Xu, W., Holmes, E.C., Gao, G.F., Wu, G., Chen, W., Shi, W., Tan, W., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 395 (10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8.

Maares, M., Haase, H., 2016. Zinc and immunity: an essential interrelation. Arch. Biochem. Biophys. 611, 58–65. https://doi.org/10.1016/j.abb.2016.03.022.

Maghbooli, Z., Sahraian, M.A., Ebrahimi, M., Pazoki, M., Kafan, S., Tabriz, H.M., Hadadi, A., Montazeri, M., Nasiri, M., Shirvani, A., Holick, M.F., 2020. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS One 15 (9), e0239799. https://doi.org/10.1371/journal.pone.0239799.

Marcos, A., Nova, E., Montero, A., 2003. Changes in the immune system are conditioned by nutrition. Eur. J. Clin. Nutr. 57 (Suppl. 1), S66–S69. https://doi.org/10.1038/sj.ejcn.1601819.

Meisel, E., Efros, O., Bleier, J., Beit Halevi, T., Segal, G., Rahav, G., Leibowitz, A., Grossman, E., 2021. Folate levels in patients hospitalized with Coronavirus Disease 2019. Nutrients 13 (3). https://doi.org/10.3390/nu13030812.

Moghaddam, A., Heller, R.A., Sun, Q., Seelig, J., Cherkezov, A., Seibert, L., Hackler, J., Seemann, P., Diegmann, J., Pilz, M., Bachmann, M., Minich, W.B., Schomburg, L., 2020. Selenium deficiency is associated with mortality risk from COVID-19. Nutrients 12 (7), 2098. https://doi.org/10.3390/nu12072098.

Mossad, S.B., Macknin, M.L., Medendorp, S.V., Mason, P., 1996. Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study. Ann. Intern. Med. 125 (2), 81–88. https://doi.org/10.7326/0003-4819-125-2-199607150-00001.

Murai, I.H., Fernandes, A.L., Sales, L.P., Pinto, A.J., Goessler, K.F., Duran, C., Silva, C., Franco, A.S., Macedo, M.B., Dalmolin, H., Baggio, J., Balbi, G., Reis, B.Z., Antonangelo, L., Caparbo, V.F., Gualano, B., Pereira, R., 2021. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA 325 (11), 1053–1060. https://doi.org/10.1001/jama.2020.26848.

Nathan, L., Lai, A.L., Millet, J.K., Straus, M.R., Freed, J.H., Whittaker, G.R., Daniel, S., 2020. Ca ions directly interact with the Ebola virus fusion peptide to promote structure-function changes that enhance infection. ACS Infect. Dis. 6 (2), 250–260. https://doi.org/10.1021/acsinfecdis.9b00296.

Ny, P., Kelsom, C., Chron, A., Lou, M., Nieberg, P., Shriner, K., Huse, H., Wong-Beringer, A., 2021. Factors associated with prompt recovery among hospitalised patients with coronavirus disease 2019. Int. J. Clin. Pract. 75 (11), e14818 https://doi.org/10.1111/ijcp.14818.

Paliogiannis, P., Mangoni, A.A., Dettori, P., Nasrallah, G.K., Pintus, G., Zinellu, A., 2020. D-Dimer concentrations and COVID-19 severity: a systematic review and meta-analysis. Front. Public Health 8, 432. https://doi.org/10.3389/fpubh.2020.00432.

Pedersen, S.F., Ho, Y.C., 2020. SARS-CoV-2: a storm is raging. J. Clin. Invest. 130 (5), 2202–2205. https://doi.org/10.1172/JCI137647.

Peterson, C.A., Heffernan, M.E., 2008. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J. Inflamm. 5, 10. https://doi.org/10.1186/1476-9255-5-10.

Radujkovic, A., Hippchen, T., Tiwari-Heckler, S., Dreher, S., Boxberger, M., Merle, U., 2020. Vitamin D deficiency and outcome of COVID-19 patients. Nutrients 12 (9). https://doi.org/10.3390/nu12092757.

Read, S.A., Obeid, S., Ahlenstiel, C., Ahlenstiel, G., 2019. The role of zinc in antiviral immunity. Adv Nutr 10 (4), 696–710. https://doi.org/10.1093/advances/nmz013.

Ricci, A., Pagliuca, A., D'Ascanio, M., Innammorato, M., De Vitis, C., Mancini, R., Giovagnoli, S., Facchiano, F., Sposato, B., Anibaldi, P., Marcolongo, A., De Dominicis, C., Laghi, A., Muscogiuri, E., Sciacchitano, S., 2021. Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients. Respir. Res. 22 (1), 76. https://doi.org/10.1186/s12931-021-01666-3.

Rowe, S., Collins, P.D., Stacey, S.E., Carr, A.C., 2021. Micronutrients and respiratory infections: the biological rationale and current state of clinical evaluation. Br. J. Hosp. Med. 82 (4), 1–8. https://doi.org/10.12968/hmed.2020.0730.

Rozga, M., Cheng, F.W., Moloney, L., Handu, D., 2021. Effects of micronutrients or conditional amino acids on COVID-19-related outcomes: an evidence analysis center scoping review. J. Acad. Nutr. Diet. 121 (7), 1354–1363. https://doi.org/10.1016/j.jand.2020.05.015.

Ryu, Y.B., Jeong, H.J., Kim, J.H., Kim, Y.M., Park, J.Y., Kim, D., Nguyen, T.T., Park, S.J., Chang, J.S., Park, K.H., Rho, M.C., Lee, W.S., 2010. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition. Bioorg. Med. Chem. 18 (22), 7940–7947. https://doi.org/10.1016/j.bmc.2010.09.035.

Rydwik, E., Anmyr, L., Regardt, M., McAllister, A., Zarenoe, R., Åkerman, E., Orrevall, Y., Bragesjö, M., Dahl, O., Kemani, M.K., Nordstrand, L., Ekman, U., Holmström, L., Nygren-Bonnier, M., 2021. ReCOV: recovery and rehabilitation during and after COVID-19 - a study protocol of a longitudinal observational study on patients, next of kin and health care staff. BMC sports science, medicine & rehabilitation 13 (1), 70. https://doi.org/10.1186/s13102-021-00299-9.

Schleithoff, S.S., Zittermann, A., Tenderich, G., Berthold, H.K., Stehle, P., Koerfer, R., 2006. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83 (4), 754–759. https://doi.org/10.1093/ajcn/83.4.754.

Serebrovska, Z.O., Chong, E.Y., Serebrovska, T.V., Tumanovska, L.V., Xi, L., 2020. Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets. Acta Pharmacol. Sin. 41 (12), 1539–1546. https://doi.org/10.1038/s41401-020-00554-8.

Sigmundsdottir, H., Pan, J., Debes, G.F., Alt, C., Habtezion, A., Soler, D., Butcher, E.C., 2007. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8 (3), 285–293. https://doi.org/10.1038/ni1433.

Silberstein, M., 2020. Correlation between premorbid IL-6 levels and COVID-19 mortality: potential role for Vitamin D. Int. Immunopharm. 88, 106995. https://doi.org/10.1016/j.intimp.2020.106995.

Skalny, A.V., Rink, L., Ajsuvakova, O.P., Aschner, M., Gritsenko, V.A., Alekseenko, S.I., Svistunov, A.A., Petrakis, D., Spandidos, D.A., Aaseth, J., Tsatsakis, A., Tinkov, A.A., 2020. Zinc and respiratory tract infections: perspectives for COVID-19 (Review). Int. J. Mol. Med. 46 (1), 17–26. https://doi.org/10.3892/ijmm.2020.4575.

St Croix, C.M., Leelavaninchkul, K., Watkins, S.C., Kagan, V.E., Pitt, B.R., 2005. Nitric oxide and zinc homeostasis in acute lung injury. Proc. Am. Thorac. Soc. 2 (3), 236–242. https://doi.org/10.1513/pats.200501-007AC.

Steinbrenner, H., Al-Quraishy, S., Dkhil, M.A., Wunderlich, F., Sies, H., 2015. Dietary S in adjuvant therapy of viral and bacterial infections. Adv Nutr 6 (1), 73–82. https://doi.org/10.3945/an.114.007575.

Sun, J.K., Zhang, W.H., Zou, L., Liu, Y., Li, J.J., Kan, X.H., Dai, L., Shi, Q.K., Yuan, S.T., Yu, W.K., Xu, H.Y., Gu, W., Qi, J.W., 2020. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging 12 (12), 11287–11295. https://doi.org/10.18632/aging.103526.

Thakur, S., Mayank, Sarkar, B., Ansari, A.J., Khandelwal, A., Arya, A., Poduri, R., Joshi, G., 2021. Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: delving deeper into the sea of possible therapeutic options in Covid-19 disease: an update. Food Chem. Toxicol. 147, 111887. https://doi.org/10.1016/j.fct.2020.111887.

Tavakol, S., Seifalian, A.M., 2021. Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment. Biotechnol. Appl. Biochem. https://doi.org/10.1002/bab.2176.

Tavilani, A., Abbasi, E., Kian Ara, F., Darini, A., Asefy, Z., 2021. COVID-19 vaccines: current evidence and considerations. Metabol Open 12, 100124. https://doi.org/10.1016/j.metop.2021.100124.

Tehrani, S., Khabiri, N., Moradi, H., Mosavat, M.S., Khabiri, S.S., 2021. Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality. Clin Nutr ESPEN 42, 313–317. https://doi.org/10.1016/j.clnesp.2021.01.014.

Tezcan, M.E., Dogan Gokce, G., Sen, N., Zorlutuna Kaymak, N., Ozer, R.S., 2020. Baseline electrolyte abnormalities would be related to poor prognosis in hospitalized coronavirus disease 2019 patients. New Microbes New Infect 37, 100753. https://doi.org/10.1016/j.nmni.2020.100753.

Tojo, K., Sugawara, Y., Oi, Y., Ogawa, F., Higurashi, T., Yoshimura, Y., Miyata, N., Hayami, H., Yamaguchi, Y., Ishikawa, Y., Takeuchi, I., Tachikawa, N., Goto, T., 2021. Author Correction: the Ushaped association of serum iron level with disease severity in adult hospitalized patients with COVID19. Sci. Rep. 11 (1), 16949. https://doi.org/10.1038/s41598-021-96408-2.

Tolossa, T., Wakuma, B., Seyoum Gebre, D., Merdassa Atomssa, E., Getachew, M., Fetensa, G., Ayala, D., Turi, E., 2021. Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: survival analysis of retrospective cohort study. PLoS One 16 (6), e0252389. https://doi.org/10.1371/journal.pone.0252389.

Torres, B., Alcubilla, P., González-Cordón, A., Inciarte, A., Chumbita, M., Cardozo, C., Meira, F., Giménez, M., de Hollanda, A., Soriano, A., COVID19 Hospital Clínic Infectious Diseases Research Group, 2021. Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. Int. J. Infect. Dis. 104, 164–168. https://doi.org/10.1016/j.ijid.2020.11.207.

Tuerk, M.J., Fazel, N., 2009. Zinc deficiency. Curr. Opin. Gastroenterol. 25 (2), 136–143. https://doi.org/10.1097/MOG.0b013e328321b395.

Vafadar Moradi, E., Teimouri, A., Rezaee, R., Morovatdar, N., Foroughian, M., Layegh, P., Rezvani Kakhki, B., Ahmadi Koupaei, S.R., Ghorani, V., 2021. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. Am. J. Emerg. Med. 40, 11–14. https://doi.org/10.1016/j.ajem.2020.12.003.

Vassiliou, A.G., Jahaj, E., Pratikaki, M., Orfanos, S.E., Dimopoulou, I., Kotanidou, A., 2020. Low 25-Hydroxyvitamin D levels on admission to the intensive care unit may predispose COVID-19 pneumonia patients to a higher 28-day mortality risk: a pilot study on a Greek ICU cohort. Nutrients 12 (12). https://doi.org/10.3390/nu12123773.

von Essen, M.R., Kongsbak, M., Schjerling, P., Olgaard, K., Odum, N., Geisler, C., 2010. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat. Immunol. 11 (4), 344–349. https://doi.org/10.1038/ni.1851.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323 (11), 1061–1069. https://doi.org/10.1001/jama.2020.1585.

Whittaker, C., Watson, O.J., Alvarez-Moreno, C., Angkasekwinai, N., Boonyasiri, A., Carlos Triana, L., Chanda, D., Charoenpong, L., Chayakulkeeree, M., Cooke, G.S., Croda, J., Cucunubá, Z.M., Djaafara, B.A., Estofolete, C.F., Grillet, M.-E., Faria, N.R., Costa, S.F., Forero-Peña, D.A., Gibb, D.M., Gordon, A.C., Hamers, R.L., Hamlet, A., Irawany, V., Jitmuang, A., Keurueangkul, N., Kimani, T.N., Lampo, M., Levin, A.S., Lopardo, G., Mustafa, R., Nayagam, S., Ngamprasertchai, T., Njeri, N.I.H., Nogueira, M.L., Ortiz-Prado, E., PerroudJr, M.W., Phillips, A.N., Promsin, P., Qavi, A., Rodger, A.J., Sabino, E.C., Sangkaew, S., Sari, D., Sirijatuphat, R., Sposito, A.C., Srisangthong, P., Thompson, H.A., Udwadia, Z., Valderrama-Beltrán, S., Winskill, P., Ghani, A.C., Walker, P.G.T., Hallett, T.B., 2021. Understanding the potential impact of different drug properties on SARS-CoV-2 transmission and disease burden: a modelling analysis. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab837.

WHO, 2020a. Coronavirus Disease 2019 (COVID-19): Situation Report – 37.

WHO, 2020b. Coronavirus Disease (COVID-19) Dashboard.

Wu, Y., Hou, B., Liu, J., Chen, Y., Zhong, P., 2020. Risk factors associated with long-term hospitalization in patients with COVID-19: a single-centered, retrospective study. Front. Med. 7, 315. https://doi.org/10.3389/fmed.2020.00315.

Yang, C., Ma, X., Wu, J., Han, J., Zheng, Z., Duan, H., Liu, Q., Wu, C., Dong, Y., Dong, L., 2021. Low serum calcium and phosphorus and their clinical performance in detecting COVID-19 patients. J. Med. Virol. 93 (3), 1639–1651. https://doi.org/10.1002/jmv.26515.

Zhang, L., Liu, Y., 2020. Potential interventions for novel coronavirus in China: a systematic review. J. Med. Virol. 92 (5), 479–490. https://doi.org/10.1002/jmv.25707.

Zhao, C., Bai, Y., Wang, C., Zhong, Y., Lu, N., Tian, L., Cai, F., Jin, R., 2021. Risk factors related to the severity of COVID-19 in Wuhan. Int. J. Med. Sci. 18 (1), 120–127. https://doi.org/10.7150/ijms.47193.

Zheng, R., Zhou, J., Song, B., Zheng, X., Zhong, M., Jiang, L., Pan, C., Zhang, W., Xia, J., Chen, N., Wu, W., Zhang, D., Xi, Y., Lin, Z., Pan, Y., Liu, X., Li, S., Xu, Y., Li, Y., Tan, H., Zhong, N., Luo, X., Sang, L., 2021. COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU. Exp. Hematol. Oncol. 10 (1), 6. https://doi.org/10.1186/s40164-021-00202-9.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G.F., Tan, W., China Novel Coronavirus Investigating and Research Team, 2020. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382 (8), 727–733. https://doi.org/10.1056/NEJMoa2001017.

Glossary;Glossary

bd: twice a day
Ca: calcium
COVID-19: Corona Virus Induced Disease 2019
DVT: deep vein thrombosis
Fe: iron
GCS: Glasgow Coma Scale/Score
ICU: intensive care unit
IL-6: interleukin-6
L-10: interleukin-10
IMV: invasive mechanical ventilation
LIPI: Lung Immune Prognostic Index
Mg: magnesium
MV: mechanical ventilation
MODS: multiple organ dysfunction syndrome
OD: once a day
P: phosphorus
PCR: polymerase chain reaction
PE: pulmonary embolism
Se: selenium
SAPS: Simplified Acute Physiology Score
SOFA: Sequential Organ Failure assessment
TNF: tumor necrosis factor
TS: total score
Vit D: vitamin D
Vit B12: vitamin B12
Vit C: vitamin C
Vit E: vitamin E
WHO: World Health Organization
Zn: zinc